Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Lexicon Pharmaceuticals (LXRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy ...

(RTTNews) - Lexicon Pharmaceuticals (LXRX) announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial showed that once-daily dosing of sotagliflozin 400 mg improved time-in-range ...

Comprised of all ACR members-in-training, the Resident and Fellow Section is more than 8,000 members strong. The RFS is led by elected officers with the goal of developing resources and policies to ...

The Commission on Breast Imaging addresses issues related to breast imaging and breast imagers including development of Practice Parameters and Technical Standards and Appropriateness Criteria as well ...

Lexicon Pharmaceuticals (Nasdaq: LXRX) has released new data from a Phase III trial showing that its drug sotagliflozin improves certain glucose control parameters in people with type 2 diabetes. The ...

Crossway+ members receive 30% off Bibles. Learn more.

Crescent Capital BDC has a well-diversified, defensive portfolio with 89.2% first-lien debt and decreasing non-accruals, indicating high portfolio quality. CCAP is sensitive to interest rate cuts ...